Health Economics›Cutaneous T-cell lymphoma›Relapsed or refractory

Relapsed or refractory

Cutaneous T-cell lymphoma · 14 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Alemtuzumab monotherapy Variant #01	—	R 132 218	7d	~15.0 mo	—	~66	~R 8 726 355 PFS proxy · indirect	—
Brentuximab vedotin monotherapy Variant #01	—	R 85 244	21d	~16.7 mo	—	~25	~R 2 131 097 PFS proxy · indirect	1
Lenalidomide monotherapy N/A - secondary systemic drug	—	R 6 361	90d	~39.0 mo	~113.8 mo	~14	~R 89 057 PFS proxy · indirect	10
Bendamustine monotherapy Variant #01	—	R 5 419	—	~16.5 mo	—	—	—	2
Denileukin diftitox monotherapy N/A - secondary systemic drug	—	R 0	21d	—	—	—	—	—
Pralatrexate monotherapy N/A - secondary systemic drug	—	R 0	49d	—	—	—	—	1
Placebo Partial	—	—	—	~4.2 mo	~8.0 mo	—	—	145
Belinostat monotherapy Variant #01 Partial	—	—	21d	—	—	—	—	—
Methotrexate monotherapy Partial	—	—	—	~3.5 mo	—	—	—	1
Bexarotene monotherapy Variant #01 Partial	—	—	336d	~3.5 mo	—	~1	—	1
Bexarotene and Pralatrexate Variant #01 Partial	—	—	28d	—	—	—	—	—
Mogamulizumab monotherapy Variant #01 Partial	—	—	7d	~7.7 mo	—	~34	—	1
Romidepsin monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	1
Vorinostat monotherapy Variant #01 Partial	—	—	28d	~3.1 mo	—	~4	—	1

14 of 14 regimens shown